Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 7, Number 2—April 2001
THEME ISSUE
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections

State of the Art

Economic Impact of Antimicrobial Resistance

John E. McGowanComments to Author 
Author affiliation: Emory University School of Medicine, Atlanta, Georgia, USA

Main Article

Table 1

Different perspectives of economic impact of antimicrobial-drug resistancea

Health-care Drug Public
Physician Patient business industry ("society")
Focus Individual Individual Care group Potential clients Population
Outcome Absence of disease Absence of disease Reduce cost of care Product sales Maximize health
Time frame Short Short Short Short, long Long
Motivation Professionalism Personal well-being Profit Profit Social good
Approach Treatment Treatment Cost containment Develop new drugs, maintain life of old drugs Reduce forces leading to resistance

aCordell RL, Solomon SL, Scott RD, McGowan JE Jr, unpub. data.

Main Article

Correction: On July 2, 2001 the following correction was made to this article in the second sentence of paragraph 1. The word "billion" replaced "million" in the phrase "...U.S.$4 to $5 million."

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO